haloperidol decanoate 50 MG/ML Injectable Solution

What the CMS Formulary Data Shows for haloperidol decanoate 50 MG/ML Injectable Solution

Per the CMS 2026 Part D formulary file, haloperidol decanoate 50 MG/ML Injectable Solution (RxNorm concept RXCUI 859867, generic name haloperidol decanoate) appears on 324 distinct formulary files spanning 5,042 Medicare Part D plan offerings - 99.5% of enrollable Part D products, near-universal placement. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.6.

Real-world access to haloperidol decanoate 50 MG/ML Injectable Solution depends on utilization management as much as tier placement: 14.2% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 34,910 Part D beneficiaries filled haloperidol decanoate 50 MG/ML Injectable Solution in 2023, with total plan-and-beneficiary spending of $16,680,427 and an average per-beneficiary annual cost of $477.81. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry haloperidol decanoate 50 MG/ML Injectable Solution today.